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1. Introduction
A class of novel cancer treatment methods in radiation therapy using intense lasers has been
investigated and developed in recent years. We review the latest status and future prospects
in this field. Radiation therapy is playing an ever increasing role in the treatment of cancer and
other illnesses, compared to other treatment options, it shows a good response with acceptable
side effects for the patient and a good cost-benefit ratio.
Radiation therapy comes in different variants, mainly external beam radiation therapy (EBRT),
where the radiation sources are positioned outside the patient, and endoradiation therapy,
where sealed radiation sources are positioned in the treatment zone, or systemic radionuclide
therapy, where unsealed radionuclides are injected into the patient’s body.
EBRT can be performed with X-rays, gamma-rays, electrons, neutrons or ion beams. Ion
beams (such as proton and carbon beams Tajima (2009)) have the distinct advantage in
reducing unwanted radiation dose on healthy tissues before and behind the tumor region
due to the Bragg peak. On the other hand, the physical installation (accelerator, gantry, and
radioprotection measures) for ion beams is larger and more costly. Laser-driven ion beams are
small and lend themselves also for the treatment of smaller tumors. For this purpose, a new
dose monitoring method is introduced, namely on-line monitoring of laser-driven ion beams
via prompt gamma ray detection.
Endoradiation therapy too can profit from advanced laser technology and laser applications.
Here laser-driven γ beams are produced by Compton backscattering of laser light from
relativistic electron beams. They are nearly monoenergetic and have a low divergence and
high brilliance. Compared to present day γ beams, new beams with much higher flux
and much better monochromaticity become available, using new techniques of intensified
interaction between laser and electron beam. Due to their much smaller opening angle
they allow focusing with refractive γ lens optics for the first time, opening a new world
of nuclear photonics. These γ beams can be employed to induce photonuclear reactions to
selectively generate new radioisotopes or nuclear isomers with high specific activity Habs
(2011). With conventional methods, such radionuclides cannot be produced in the required
quality or quantity, but they will become available with γ beams. Thus, e.g., in many cases
"matched" pairs of isotopes of the same element become available, one for therapy and one
for diagnostics, allowing for an optimized therapy. Some new isotopes kill the cancer cells
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due to the short-range interaction only in a small volume, making a very localized treatment
possible. This will be outlined in detail in Section 3 of this chapter.
We present here one possible school of thought for these goals based on an oncological
consideration. This idea is based on the following observation Abe (2007); Molls (2009).
Dr. Molls argues: “In chemotherapy the tumor cell kill depends on the transport of the
substance to the clonogenic cells and molecular targets, DNA repair capacity, repopulation,
pO2, pH, etc. In macroscopic tumors not all the subvolumes of the tumor, clonogenic cells
and relevant molecular targets are reached by those doses of the medical substance which
are needed for cell kill. In other words,” he goes on, “the chemotherapy dose distribution
is intrinsically inhomogeneous.” On the other hand, Dr. Molls points out, “In radiation
therapy the tumor cell kill depends on intrinsic radiation sensitivity, DNA repair capacity,
repopulation, oxygenation status etc. However, the entire tumor can be irradiated matched
with the dose, which is necessary to kill all clonogenic tumor cells, even the most resistant
ones.” In other words, “it delivers a matched dose distribution,” citing the superior feature of
radiation therapy.
The process in the detection of small and even micro tumors by such methods as phase
contrast imaging Pfeiffer (2006) gives us hope for such a vision. Such techniques point
us towards small (or even micro) tumor detection. For proton laser-driven (or ion) beam
radiotherapy, the therapy of small tumors is well suited.
2. Laser-driven ion therapy
2.1 New trends in ion acceleration
It is important to improve the laser ion interaction in both its energy and the quality of the
beam. The progress in recent years makes us hopeful. Energetic proton and ion beams with
high beam quality, such as quasi-monoenergetic spectra, have been produced in the last few
years from thick metallic foils (e. g. µm thick aluminum) irradiated by ultra intense short laser
pulses with appropriate target preparations Hegelich (2006); Schwoerer (2006); Snavely (2000);
Ter-Avetisyan (2006). Most previous experiments fall in the regime called TNSA (Target
Normal Sheath Acceleration) using what we regard as relatively thick targets ((∼ µm) Fig. 1).
In this regime electrons are first accelerated by the impinging intense laser pulse and penetrate
the target. Leaving the target at the rear side, the electrons set up an electrostatic field that is
normal to the rear surface of the target. Ions accelerated from solids originate primarily from
contaminant layers of water vapor and hydrocarbons on the target surface. As these targets
are thick, the laser pulse is mostly reflected and the conversion efficiency of laser energy
to ion energy is normally less than 1 %, the maximum energy scales with less than a linear
function of the laser intensity. The maximum proton energy based on the TNSA mechanism
has not improved since 2000 (∼ 60 MeV). As reviewed by Robson et al. Robson (2007) (in
particular their Fig. 1a), their fit of the data experimentally obtained (what they collected are
all TNSA) shows that ion energies are proportional to the square root of the laser intensity
IL, which is proportional to a
2
0, where the dimensionless normalized vector potential a0 is
defined as: a0 =
e EL
mecωL
=
(
IL [W cm
−2]·λ2L [µm2]
1.37·1018
)1/2
, where me is the electron mass and ωL the
laser frequency. In TNSA, the laser energy is absorbed at the front surface of a solid target.
Hot electrons are generated by a variety of mechanisms. Since electrons gain kinetic energy
through interaction with the laser, typically up to the ponderomotive potential
ε0 ≈ eΦ = me c2
(√
1 + a20 − 1
)
, (1)
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Fig. 1. Schematic picture of “Target Normal Sheath Acceleration” (TNSA, left)Wilks (2001)
and Coherent Acceleration of Ions by Laser (CAIL, right), in particular Radiation Pressure
Acceleration (RPA). The dynamics of electrons remains coherently slaving to the laser fields,
in sharp contrast to TNSA Tajima (2009).
the electron energy gain is approximately proportional to a0, when a0 is much greater than
unity (which is the case for the data analyzed). Then through certain mechanisms the heated
electrons transmit their energy to ions, which is again thus proportional to a0.
In the present review, however, we would like to report the progress that now emerges with
a new class of experiments and theory that supports such experiments, in which a regime
of much more efficient and possibly higher energy acceleration processes exists. We will
scrutinize the process of this energy transfer between electrons and ions, both for TNSA and
the new regime that we now describe as Coherent Acceleration of Ions by Laser (CAIL), i. e. a
regime of interaction more direct than TNSA. However, it is worthwhile to look at one aspect
of the laser interaction with electrons. At higher laser intensities above 1022 W/cm2, numerical
simulations seem to indicate that a laser could also accelerate protons to high energies Bulanov
(2009). With a compact high-repetition laser system, however, the highest proton energy is
still lower than 20 MeV in all experiments Fuchs (2006). In order to realize 200 MeV/u beams
for proton/ion therapy, the laser intensity required should be as high as 1022 W/cm2 Fuchs
(2006).
Experiments, producing high-energy ions with sub-micrometer to nanometer thick targets
that are much thinner than those used so far, have shown far superior acceleration
201ase -Driven Radiation Therapy
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characteristics Henig (2009) and have recently attracted strong interest. A typical physical
situation is depicted in the sketch in Fig. 1. With the emerging nanometer target of
diamond-like carbon (DLC), the conversion efficiencies are one to two orders of magnitude
higher (> 10 %) even with modest-energy lasers (less than 1 Joule per pulse, and highly
repetitive lasers) compared with those in the regime of TNSA with the thicker targets, and
so the laser pulse can accelerate the ions to higher energies. The experiments show that the
proton energy increases as the target thickness decreases for a given laser intensity, and that
there is an optimum thickness of the target (several nm) at which the maximum proton energy
peaks and below which the proton energy now decreases.
This optimum thickness for the peak proton energy is consistent with the thickness dictated
by the relation Esirkepov (2006); Liu (2008); Matsukado (2003); Rykovanov (2008)
a0 ∼ σ = n0 dnc λL
, (2)
where σ is the (dimensionless) normalized electron areal density, n0 the electron density of the
target, and nc is the critical density. Note that this optimum thickness for typically available
laser intensities is much smaller than the previously attempted target thicknesses (for ion
acceleration). Thus we attribute the observed singularly large value of the maximum proton
energy in the recent experiments Steinke (2010; 2011) to the ability to identify and provide
prepared thin targets of the order of nm to reach this optimum condition. In reality, at this
target thickness the laser field comes to the point of partial penetration of the target, rendering
the realization of optimum rather sensitive. The experiments show that transparency plays an
important role in energy enhancement. As we shall show, in this new regime (CAIL) with
σ/a0 of the order of unity (as opposed to σ/a0 ≫ 1 in TNSA), the electron dynamics remains
coherent, directly following the laser field. Thus we call this regime of acceleration Coherent
Acceleration of Ions by Laser (CAIL).
2.2 How ions are accelerated with laser and electrons
The characteristics of the previous laser ion acceleration experiments (TNSA) are that (i) laser
ion acceleration has great potential, particularly in its accelerating gradient (of the order of
TeV/m) and thus compactness of acceleration; (ii) however, its progress has lagged since the
initial observation Clarke (2000); Maksimchuck (2000); Snavely (2000) in 2000 in enhancing its
energy and other aspects with less energy laser drive, often limited to several MeV energy gain
Fuchs (2006); Robson (2007); (iii) further, the energy spectra of ions remain broad Fuchs (2006),
except in exceptional cases Hegelich (2006); Schwoerer (2006); Ter-Avetisyan (2006); and (iv)
the efficiency remains low Fuchs (2006). On the other hand, although the numbers achieved
are so far not overwhelming, some reports indicate one or two possible ways out, when, for
example, the plasma density is near the critical value Matsukado (2003); Yogo (2007).
The above situation may be broadly summarized as follows. The intense laser somehow
heats electrons of the solid target to high energies, which contributes to a large space charge
separation on a rapid time scale of electron runaway from the surface of the target (the rear
surface), which pulls ions and makes them run after the escaped electrons. The electron
heating involves complex processes, both coherent and individual particle processes (such
as collisions), and the original electron motion in the intense laser field is cascaded down to a
thermal spectrum of electrons that drive ions as described above. Firstly, this means that the
electron spectrum is broadly spread (such as Maxwellian) and is certainly limited to or less
than the ponderomotively driven electron energy of mec
2
√
1 + a20. The scaling to the intensity
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of the laser never greatly exceeds
√
IL, as shown in the limiting energy of electrons McKenna
(2007); Robson (2007). Secondly, hot electrons suddenly escape from the target, so that the
ions are unable to follow the electrons with the result that some fraction of these electrons
run away from the ions and the rest of them are pulled back toward the ions. The ions are
unable to be smoothly accelerated; in other words, the gradual (adiabatic) acceleration process
is nonexistent. This non-adiabatic nature of the ion dynamics is the underlying reason for
exhibiting properties (ii) – (iv). These features arise essentially from the mismatch between the
group velocity of photons and the velocity of electrons subsequently energized and that of the
ions. The ions remain slow and non-relativistic, while photons and electrons are relativistic.
Thus, our principal direction is first to utilize the photon energy more directly rather than
cascading through multiples of collisional processes, and secondly to transfer laser energy to
electron energy and to ions more adiabatically. When the solid target is too thick, most ions
remain stationary and the momenta of photons are spread over broadly. Thus we should
limit the number of ions influenced by laser acceleration. Secondly, in order that the twofold
interaction process of laser to electrons and from electrons to ions becomes more gradual, we
need to slow down the photons and electrons and make them match the sluggish ions, at least
initially, until they reach high speed Mako (1984). Laser electron acceleration Tajima (1979)
may be easier in this sense, because light electrons at rest may be more easily trapped by the
speeding photon-driven waves, whose velocity is near c, whereas the trapping velocity width
Esaray (1995) is
√
eΦ/me ∼ c, where Φ is the ponderomotive potential. This ponderomotive
potential is capable of inducing the wakefield with amplitude of the order of Ew ∼ meωp c/e.
This is why in the laser electron acceleration the fast wakefield vgr ∼ c can still trap stationary
electrons (“self-injection"). Meanwhile for ions
√
eΦ/mi ≪ c, and this value can only become
∼ c, when a0 = O(mi/me) (ultrarelativistic), where mi is the mass of ions. More importantly,
in order to trap ions, the trapping velocity width of ions is much smaller than that for electrons
vi,tr ∼
√
me
mi
a0 Q c , (3)
where Q is the ion charge in units of e (electron charge). Thus, in the regime of our interest 1 ≤
a0 ≪ mi/me the accelerating structure has to move at a velocity within this vi,tr ≪ c. For ions
to obtain net energy gain, the ion velocity needs to be within the trapping separatrix, which
is situated over the velocity band that is centered at the phase velocity vph of the accelerating
structure (we will call it a “bucket” later in Sec. 2.4.3) with a trapping width vi,tr. Ions outside
of this band (either above or below) simply oscillate in energy, but obtain no net energy gain.
Even when the bucket velocity vph increases in time, ions that are trapped deeply enough may
be kept trapped and, therefore, continue to gain energy from the bucket. This is the principle
of gradual acceleration. Either when the velocity vph increases too suddenly or when ions are
outside of the trapping separatrix, ions spill out or are left out of the accelerating structure.
In order to accomplish the first goal, one way is to adopt a very thin foil so that the mass
contained in this foil is tiny. Alternatively, a diluter medium such as a dense gas or matter
with clusters could be used. In order to accomplish the second goal, the most direct way to
do so is to choose the density of the target material to result in a vanishing group velocity
of photons such that ions can respond adiabatically. In this regard, it further helps if we can
control the velocity of the accelerating structure to match the accelerated ion velocity. These
considerations lead us to consider to look at very thin foil targets and alternatively at matter
at or close to the critical density.
203ase -Driven Radiation Therapy
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Another consequence of this general consideration entails a strategy to slow down the electron
motion after they are emitted from the target. This may be done by providing a concave
geometry of the surface Tajima (2005) or other target preparations. One of the recent hopes
is to employ circularly polarized laser pulses (CP). These, unlike the linearly polarized laser
pulses, do not have sudden high frequency (2ωL) motions by linearly polarized photons, but
only result in a smooth ponderomotive acceleration of the target Klimo (2009); Macchi (2005);
Qiao (2009); Robinson (2008); Rykovanov (2008). If the CP ideally works, the ponderomotive
force on electrons induces and matches the electrostatic force generated between the charge
separated ions and electrons, and this keeps the overall dynamics smooth and adiabatic. A
somewhat extreme and earlier rendition of this concept may be that of the radiation dominant
acceleration by Ashour-Abdalla et al. Ashour-Abdalla (1981) and Esirkepov et al. Esirkepov
(2004), where the laser photon pressure drives electrons to relativistic speed that drags ions
also to relativistic speed closely following the electrons.
2.3 CAIL and RPA experiments
In this section we present recent experimental progress on laser ion acceleration, which shows
marked improvements over experiments in the regime of TNSA: in (i) the total conversion
efficiency of laser energy into ion energy, (ii) the maximum observed ion energies, and (iii)
the production of monoenergetic peaks in the ion energy spectra. We compare these results
to previous experiments, which are based on the TNSA mechanism, established over the last
10 years in experimental and theoretical efforts. In TNSA one has observed for certain laser
parameters, e.g. 1 PW lasers with 500 fs, maximum conversion efficiencies of 12 %, or one
has observed maximum proton energies of 58 MeV Snavely (2000) and by filtering out small
target regions could produce quasi-monoenergetic ion spectra Hegelich (2006); Schwoerer
(2006); Ter-Avetisyan (2006). At present, similar experimental values of efficiency, energy,
etc. can be obtained with much smaller lasers. The formerly predicted laser parameters
based on TNSA Robson (2007) to reach ion energies of 240 MeV for protons or 450 MeV/u
for carbon ions for medical therapy facilities have been rather big and the laser would end up
costly. The new regime, where coherent dynamics of electrons in accelerating ions by laser
(CAIL) plays a significant role, can yield scaling laws that lend to a prospect that short-pulse,
high-intensity lasers with high repetition rate may drive ion beams competitive with classical
radio-frequency accelerator systems.
2.3.1 Laser ion acceleration with ultra-thin foils (CAIL)
In order to realize the CAIL regime, one wishes to employ nanometer thick target foils together
with high-intensity short pulse lasers. In search of ultra-thin free standing foils that withstand
strong ion and electron bombardment, DLC foils appear to be eminently suited. They have
a very high tensile strength, large hardness, good heat conduction, high heat resistance and,
when used as stripper foils, they show a large survival rate for ion bombardment. With a
special production technique free-standing foils with 75 % sp3 bonds – diamond-like bonds –
can be produced.
The thickness of the DLC-foils has been characterized by means of an atomic force microscope
(AFM) with an accuracy close to 0.5 nm Tajima (2009). Furthermore, the detailed depth
composition – showing also front layer contaminations – was measured via Elastic Recoil
Detection Analysis (ERDA)Tajima (2009).
A second ingredient in these laser acceleration experiments Henig (2009); Steinke (2010) is
an ultra-high contrast of the laser pulses to avoid the preheating and expansion of the target
before the interaction with the main laser pulse. The intensity of prepulses and the amplified
204 Current Cancer Treatment – Novel Beyond Conventional Approaches
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Fig. 2. Maximum cutoff ion energies as a function of target thickness in the regime of CAIL
experiments Henig (2009). Theoretical curves are from the CAIL theory. Observed values
and theory (CAIL) are in good agreement over a broad parameter range. The optimum
condition is realized at a thickness parameter σ ≈ a0 Tajima (2009).
spontaneous emission (ASE) pedestal are characterized with a 3rd order auto correlator,
yielding typical values of 10−7 at 10 ps before the main pulse. This value was further
improved by a recollimating double plasma mirror, which lets the low intensity prepulse
pass through, while it reflects the high intensity part of the pulse. In this way an estimated
contrast of ∼ 10−11 was achieved. For the longer laser pulses the contrast was improved by
Self-Pumped Optical Parametric Amplification (SPOPA) Shah (2009), using nonlinear optical
effects and thus avoiding the 50 % energy loss of the double plasma mirror.
Ultra-thin foils in two regimes have been investigated so far: (i) for laser pulses of 45 fs
duration at the laser of the Max-Born Institute (MBI) in Berlin and (ii) for laser pulses with
700 fs duration at the Trident laser in Los Alamos. Laser accelerated ions were measured with
a Thomson parabola spectrometer.
2.3.2 Characteristics with ultra-thin targets
Let us now discuss jointly all results for ultra-thin targets in comparison to the thicker targets
results, where TNSA is the dominant acceleration mechanism.
In Fig. 3 we compare the conversion efficiency from laser energy to ion energy. At the
optimum target thickness and 45 fs laser pulses, an optimum conversion efficiency of 10 %
for laser energy into ion energy was obtained by integrating all protons above 2 MeV and
all carbon ions above 5 MeV for the linearly polarized laser. Correspondingly, ∼ 9 % was
obtained for circular polarization. For the 700 fs experiment a lower efficiency of about
2 % was observed. The values are shown in Fig. 3 in the comparison of the CAIL results
with efficiencies for thicker foil targets (TNSA). We show the general trends of the TNSA
mechanism by theoretical results from the fluid model Fuchs (2006), which describes the
experimental data quite well. In addition, we show specific experimental results for the
ASTRA laser Spencer (2003), the RAL PW laser McKenna (2004) and the NOVA PW laser
Snavely (2000). We observe approximately a 50 fold increase in conversion efficiency for thin
targets with the 45 fs pulses compared to TNSA at the same laser intensity, also taking our
205ase -Driven Radiation Therapy
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Fig. 3. Left: Conversion efficiency of laser energy to ion energy comparing results from thick
targets and the TNSA mechanism to measurements with ultra-thin targets in the regime of
CAIL (red diamonds and line). For the TNSA mechanism smooth curves from the fluid
model by J. Fuchs Fuchs (2006) are shown together with some experimental points: ASTRA
Spencer (2003), NOVA Snavely (2000), RAL McKenna (2004). Right: Maximum cutoff
energies of ions given in MeV/u as a function of laser pulse duration. The energy gain by
CAIL experiments is embedded with red dots in the predicted curves of TNSA. Note that in
shorter pulses, energies by CAIL are more than an order of magnitude higher than for TNSA.
Here also the results from the cluster target of Sec. 3.1.3 are shown Tajima (2009).
own measurements at larger target thicknesses into account. For 700 fs pulse duration the
efficiencies of thick target TNSA results and thin target results are comparable. If one increases
the pulse duration, for short pulses the optimum target areal electron density σ ≈ a0, while
for longer pulses σ has to be significantly larger to reach the maximum cutoff energy. Here
one first has to reach the relativistic transparency of the target by expanding the target (see
Sec. 2.4.2), explaining in part the reduced conversion efficiency. For somewhat shorter laser
pulses and cold adiabatic RPA, a 60 % conversion efficiency has been predicted theoretically
for higher laser intensities in an idealized 1D PIC simulation Robinson (2008). Experimentally,
the optimum conditions depend on many parameters such as optimum laser focusing to
prevent heating of the walls of the bulged out target Klimo (2009).
In Fig. 3 we compare the maximum cutoff ion energy for protons and carbon ions between
measurements with ultra-thin targets and µm thick targets, where the TNSA mechanism
dominates. In Fig. 3 for TNSA only proton energies are shown for model calculations, which
reproduce the experiments quite well Fuchs (2006). Approximately an increase by a factor of
10 is observed for the short laser pulses of 45 fs in the cutoff energies between TNSA and CAIL.
An overall increase in energy occurs for both processes for longer laser pulses. At the PW level
the proton energies for TNSA vary from 58 MeV Snavely (2000) to 13 MeV McKenna (2004)
for similar pulse energies of 500 J and 400 J. Thus it is difficult to obtain a good comparison
with the results of ultra-thin targets. For the carbon ions and the longer pulse of 700 fs, a
factor of 4 higher energies were observed for a factor of 4 smaller pulse energies, pointing to
a clear advantage of the ultra-thin targets in CAIL. For the short pulses of 45 fs again an order
of magnitude improvement is seen for the ultra-thin targets (CAIL).
2.3.3 Cluster target experiments
Fukuda et al. Fukuda (2009) explored a different path of laser ion acceleration for hadron
therapy: They use a gas jet target mixed with submicron clusters. The target consists of a He
gas jet with a density of 1.5 · 1019 cm−3, into which solid-density CO2 clusters with an average
diameter of several 100 nm are dispersed at a cluster density of 3 · 109 cm−3. This constitutes
206 Current Cancer Treatment – Novel Beyond Conventional Approaches
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an average density at or near the critical density. A well-formed self-channeling phenomenon
coincides with the detection of high energy ions. They observe in their ion spectrometers
rather high ion energies in the range of 10− 20 MeV/u for carbon, oxygen, or helium ions
with a small divergence angle of 3◦ Fukuda (2009; 2011). This maximum energy value is
much higher than expected from TNSA.
It is noted that the average density near the critical density may have played an important
role, perhaps similarly to Matsukado et al. Matsukado (2003) and Yogo et al. Yogo (2007).
In these experiments the enhancement of ion energies was noted when the density is in the
neighborhood of the critical value. Thus the acceleration with clusters has commonality
with the dynamics observed in the long pulsed thin target (Sec. 2.4.2) after the laser burns
through the target (see also Sec. 2.4.2), when the density becomes critical through relativistic
transparency. Near the critical density, as we noted, the group velocity of photons is small.
In recent simulations Kishimoto (2009) the maximum ion energy is observed to scale with
the pulse length, with the intensity fixed, and inversely proportional to the size of the
clusters. Thus the nano-structured targets may provide an enhanced coupling of laser and
ions Kishimoto (2000). Higher efficiencies may be obtained by increasing the pulse energy,
the contrast of the laser and using much smaller clusters with higher density.
Recently, ion acceleration up to 50±25 MeV/u has been achieved using the cluster-gas
target with the 20 TW (40 fs, 800 mJ) J-KAREN laser system Fukuda (2010) and five times
more power than the earlier experiment. If we combine the two experimental results, an
extrapolation shows that a 100 TW-class Ti:Sa laser is capable to generate 200 MeV/u ions.
In addition, particle-in-cell simulations have delivered an energy scaling of ions generated by
the magnetic vortex acceleration in near-critical density plasmas Nakamura (2010), providing
a possible acceleration mechanism for the cluster-gas targets. The scaling suggests that a 100
TW-class laser is capable to generate 200 MeV protons, consistent with the experiments.
Therefore, both experiments and theory predict that 100-TW class Ti:Sa lasers, which are
achievable using the present laser technologies, reach the ballpark of 200 MeV ions applicable
to medical use. Such experiments will be conducted in the near future.
2.4 Towards more efficient and gradual acceleration
have been motivated by much thicker the TNSA regime electrons are first accelerated
impinging relativistic laser pulse and they penetrate the target target at the rear side, field
that points normal to was the origin of the terminology of the TNSA Most electrons are forced
to turn around quasi-stationary assumed to follow a thermal studies of the conventional
Most of the theories for thicker targets are based on TNSA Andreev (2008); Ceccotti (2002);
Mora (2003; 2005); Passoni (2004; 2008). Though this mechanism is widely used in the
interpretation of the experimental results, it does not apply to the ultrathin nanometer scale
targets because the direct laser field and partially transmitted laser pulse play an important
role in electron dynamics and the energetic electrons oscillate coherently, instead of showing
chaotic thermal motion. In order to design a compact accelerator with a modestly intense
laser for medical applications we discuss here, it is desirable to understand the new emerging
regime that is promising for this purpose.
2.4.1 Efficient energy gain in the CAIL regime
In case of a thin target, electron motions maintain primarily those organized characteristics
directly influenced by the laser field in the CAIL regime, rather than chaotic and thermal
motions of electrons resulting from laser heating on the front surface, where the laser is either
absorbed or reflected for the TNSA regime.
207ase -Driven Radiation Therapy
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It may be instructive to compare conceptual differences of the regime of TNSA and that of
CAIL. See Ref Tajima (2009) for details. In the TNSA case the laser interacts primarily at the
front surface of the target, while in all cases of the CAIL interaction takes place at the rear
surface. In the regime of TNSA electrons that have gained energy at or near the front surface
propagate through the target and escape from the rear surface with a broad energy spread. In
a model problem Mako (1984); Tajima (1978) in which the electron beam (with a delta-function
energy spectrum) enters from the metallic surface that may be regarded as the rear surface,
the energy gain was analyzed. In CAIL, once the laser penetrates the target and electrons gain
energy from the laser, the electron dynamics in the presence of the rear surface is once again
similar to this process.
In an ultra-thin target, the laser electromagnetic fields largely sustain coherent motions of
electrons. As partially or fully penetrated laser fields in addition to the laser fields in the
target, the electron motion under laser fields is intact and is characterized by the transverse
field. The electron energy consists of two contributions, the kinetic energy of (organized)
electrons under the laser and the ponderomotive potential of the partially penetrated laser
fields that help sustain the electron forward momentum. Following the analysis of Ref. Mako
(1984); Tajima (2009), the maximum ion energy is
εmax,i = (2α+ 1) Q ε0, (4)
where ε0 is given by Eq. (1). The enhancement of the ion energy gain in Eq. ( 4) in the CAIL is
due to the factor (2α+ 1) compared with the equivalent TNSA energy gain Eq. (1). In Eq.( 4)
we see that the ion energy is greater if the coherence parameter of electrons α is greater: (a)
the energy gain of the present case is several times higher than that of TNSA; (b) the energy
gain maximizes at the optimum thickness of σ ≈ a0 mentioned earlier in Sec. 2.1 for CAIL, as
opposed in a much thicker target for TNSA. These features are also seen in Fig. 4 later.
2.4.2 Relativistic transparency
Understanding the dynamics of the laser pulse and the target evolution is important when
the pulse is longer (∼ hundreds of fs) than tens of fs and / or the target is thicker than a
few nm. We now consider the cases when the target is thicker ((σ/a0) ≫ 1) than when it is
immediately influenced by the laser fields, but still σ/a0 is less than for TNSA. In this case
the laser does not immediately penetrate through the target. We can delineate at least three
stages. The first stage is similar to the situation we described above for σ ≈ a0. The laser just
impinges on the thin surface layer of the dense target. The second stage starts when the target
begins to expand by the laser interaction, primarily in the direction of laser propagation until
the plasma becomes relativistically transparent at time t1. After this relativistic transparency
time t1, the plasma expands in all three dimensions. The third stage begins when the plasma
becomes underdense at time t2 (the classical transparency time) and lasts until the pulse is
over.
One of the distinguishing features of the thin target CAIL regime, as compared with TNSA, is
the presence of the relativistic transparency time t1 before the pulse length τ, so that the laser
pulse emerges or interacts with the entire target before the pulse is gone. We find this time to
be Yan (2009a)
t1 ∼=
(
12
pi2
)1/4 N1/2
a1/20
(τd/Cs)
1/2 . (5)
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Fig. 4. The maximum ion energy driven by the laser pulse as a function of target thickness in
the regime of CAIL. The optimum is reached at ξ = (σ/a0) ∼ 5. Energies for thicker targets
decrease from this value, eventually leading to the value often found in the TNSA regime
(µm or more in this graph). C6+ energy gain estimated from Eq.( 7) as a function of target
thickness and with α ∼= 3. (For a given laser pulse length at 700 fs and laser amplitude
a0 = 20). The contribution of the electron energy gain after the relativistic transparency has
been reached is dominant Tajima (2009). The experimental points by Hegelich et al., Hegelich
(2011) closely follow the theoretical prediction
Here the sound speed Cs ∼= (Qme c2a0/mi)1/2 and N = n0/nc. The relativistic transparency
time t1 in Eq.( 5) is approximately the geometrical mean of the laser pulse length τ and the
traverse time over the target by the sound speed.
Yin et al. Yin (2007) have found in their 3D simulation that for long pulse irradiation the
pulse exhibits an epoch of burn-through (and relativistic transparency). This phenomenon is
when the laser penetrates the target and eventually emerges from the rear end of the target.
This corresponds precisely to the second period between t1 and t2 and in fact most of the
acceleration takes place shortly after t1. We now characterize the physical processes including
these phenomena. Beyond time t1, the plasma is relativistically transparent so that the laser
can now interact with the (expanded) target plasma in its entirety. It can also now expand in
three dimensions. For 3D isotropic expansion, it takes time ∆t during which the normalized
density reduces from γ to 1Yan (2009a) as:
∆t =
Nd(γ1/3 − 1)
γCs
1
sin((pi/2τ)t1)
. (6)
Now the time t2, when the plasma becomes underdense, is given as t2 = ∆t + t1 .
We examine the physical situation at time t1, when the laser pulse has penetrated the entire
target with the relativistic transparency and we may regard that the laser begins to drive the
entire plasma electrons from this already expanded target. An expression in a closed form for
the ion energy gain between time t1 and t2 in the case of a laser pulse with a duration longer
than the relativistic transparency (rt) time t1 has been obtained expanding the idea in Eq. ( 4)
as:
εmax,i,rt = (2α+ 1) Qε¯0
(
(1 +ωL(t2 − t1))1/2α+1 − 1
)
. (7)
In Fig. 4 we plot the total energy gain in the case of carbon ions from this formula as a
function of target thickness. Once again the optimum thickness, for which the ion gain is
maximum, is sharply realized in the CAIL regime. Towards the TNSA regime the ion energy
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decreases substantially. Thus theory has guided the experiments that (remakably) agree with
the predictions Hegelich (2011).
It is noteworthy to consider how the photon pulse behaves right after the relativistic
transparency time t1. The group velocity of the laser pulse vgr = c
√
1−ω2p/ω2L vanishes
at t = t1. At this moment the ponderomotive structure of photons is stationary, which pushes
electrons as well as ions effectively forward. This is because the heavy and sluggish ions can
respond easily to this stationary potential. As the laser penetrates further and the plasma
density decreases below ncr · γ, the group velocity begins to increase. In our model case Yan
(2009a) of the laser temporal structure of a0 ∝ sin
2((pi/2τ)t), the group velocity increases as
vgr(t) ∼ 2c cot((pi/2τ)t1)
√
(pi/2τ)(t− t1) . (8)
This means that the speed of the accelerating structure – made up of the electron layer driven
by the laser ponderomotive force and the ion layer that is attached to the former by the
electrostatic force – is picking up quickly from zero. This suggests that if we can slow down
the photon group velocity, the rate of increase of the photon group velocity and thus the
accelerating structure is reduced and, therefore, the adiabatic nature of acceleration becomes
more pronounced. Such may be accomplished by increasing the density of the plasma behind
the solid target by a further material. Nakamura et al. Nakamura (2010) have investigated
near critical density acceleration, which is related to this point as seen in Eq.( 8).
2.4.3 Radiation Pressure Acceleration (RPA)
Mono-energetic ion beams are one of the important requirements of ion beam therapy. The
Coherent Acceleration of Ions (CAIL) by linearly polarized pulses can efficiently accelerate
ions to higher energy by using nanometer targets. Recently, theoretical attention has focused
on the use of circularly polarized (CP) laser pulses in the CAIL regime to accelerate high
density ion bunches at the front surface of thin foils. For CP pulses, the ponderomotive force
has no oscillating component as discussed; hence, electrons are steadily pushed forward,
inducing a charge separation field which can accelerate ions. It is expected to provide a
more adiabatic interaction so that mono-energetic ion beams may be realized, in this case in
the regime called Radiation Pressure Acceleration (RPA). There is a regime of phase stable
acceleration in the interaction of a CP laser with a thin foil in a certain parameter range,
where the proton beam is synchronously accelerated and bunched like in a conventional radio
frequency (RF) accelerator. This synchronous acceleration leads to the acceleration regime
in which the position of ions is well tied with the accelerating structure made up of the
laser ponderomotive potential and the electron layer. Therefore, ions may be trapped in this
accelerating bucket, in which they may show a phase-stable behavior. That is, ions exhibit
phase stable oscillations (synchrotron oscillations).
A simple model to elucidate the bunch formation in the phase stable acceleration has been
considered Yan (2009a). We introduce the relative ion position ζ = (xi − xr) with the
compressed electron layer −ls/2 ≤ ζ ≤ ls/2, where xr = D + ls/2 represents the position
for the center-of-mass reference particle. The force acting on a test ion is given by Fi =
qi Em (1− (xi − D)/ls). Thus, the equation of motion for the proton is
d2xi
dt2
=
Qe Em
mi
(
1− xi − D
ls
)
. (9)
Eq.( 9) shows that the center of mass xr moves with constant acceleration as
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xs = (1/2)(d/2)ω
2
pit
2, (10)
where ω2pi = 4pie
2Qn0/mi, d and n0 are the original foil thickness and electron density. The
phase motion (ζ, t) around xr is showing oscillatory motions:
ζ¨ = −Ω2ζ, Ω2 = Qe 4pien0d
mi ls
, (11)
where Ω is called the frequency of the synchrotron oscillation motion in longitudinal
direction Chao (1999). This means that the center of mass accelerates with a constant rate
(in the nonrelativistic regime) as in Eq.( 10), while the individual ions oscillate around the
center trapped by the bucket.
The bucket velocity width may be determined from Eq.( 11):
vi,buc = ζΩ =
√
me
mi
Q a0 c N
−1/4 . (12)
This bucket size is close to (and slightly less than) the trapping velocity width from Eq.( 3). As
long as N > γ (or t ≤ t1), vi,buc ≤ vi,tr, while for N < γ (t > t1) vi,buc ≥ vi,tr and some of the
ions in the bucket begin to spill over.
The energy spread of trapped ions in the bucket of the accelerating structure with respect to
the energy εr of the reference particle is
∆ε/εr = 2 ζ0 Ω/
√
2 mi εr . (13)
If we take ζ0 = ls/2 and εr = 400 MeV, the energy spread will be less than 4 %, which agrees
well with the simulation results.
In 1D simulations the plasma is kept cold and the target is pushed forward as a whole, so an
ideal mono-energetic ion beam can be generated. A quasi-monoenergetic carbon ion beam
with 17 % energy spread has been observed in recent experiments Henig (2009): ∆ε/εr ∼
17 % is about 3 times higher than the estimation by Eq.( 13) because of the multi-dimensional
effects. In real situations typically the laser intensity is not uniform, the transverse profile
tends to bend the flat target, and foil electrons are heavily heated by the oblique incident laser,
in spite of the CP pulse. If and when electrons become hot or the laser leaks through, the
bucket begins to collapse and the energy spread drastically increases.
2.4.4 Improved acceleration schemes
When the electron dynamics is slow enough that ions evolve less suddenly, i. e. adiabatically
Chao (1999), the final energy gain of electrons (and thus that of ions) may not be that of the
instantaneous energy dictated by the expression of ε0. For example, we have remarked a
case with a circularly polarized pulse. In the latter, for example, the pulse should cause less
electron energy gain than in the linearly polarized case. Therefore, the cloud of electrons
cannot instantaneously shoot out of the foil, but rather leaves the target gradually. This
renders a possibility that the electron energy is not only proportional to the field strength
(as proportional to a0), but also to the time during which electrons are accelerated by v× B if
this is much longer than the laser period. When electrons substantially co-move with the laser
pulse, this time can be proportional to a0 or some fraction of it, leading to a proportionality
greater than a0 such as a
2
0. We anticipate more results to come in advancing the ion energy by
laser acceleration spurred by the current theoretical understanding of the physics.
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Fig. 5. Maximum proton energy versus a0 obtained in 2D PIC simulations. In the modest a0
regime (15 ≥ a0 > 1) the energy gains by LP and CP are not much different, while that by CP
is much greater than by LP for large a0 (a0 ≥ 15). The exponent to a0 for CP seems to increase
from less than 2 in a0 ≤ 15 towards 2 in a0 ≥ 15.
In PIC simulations, an a20 scaling is observed in Rykovanov (2008) using circularly polarized
(CP) laser pulses. However, this is only a 1D simulation and bending and boring effects are not
considered. With 2D simulations, the scaling with the normalized vector potential a0 is only
a1.10 in the linear polarized case (and the fit looks much better than Eq.( 1), while for the circular
case the maximum proton energy scales with a1.60 at the lower intensity for a0 ≤ 30. It tends
to be closer to an a20 scaling for larger a0 values (see Fig. 5), including the highly relativistic
regime Esirkepov (2004). This tendency of having less energy (or a smaller exponent to a0)
in the 2D simulation than the one shown in the idealized 1D model, may be due to several
reasons. One is the bending or bulging (the convex shaping as viewed from the rear surface,
where ions are emitted) of the thin target by the impinging laser pulse. This causes the excess
plasma electron heating by the obliquely incident laser electric fields and thus contributes
to hot electrons that run away from the target leaving ions far behind, yielding non-adiabatic
electrons and thus ion dynamics. Secondly, once the laser ponderomotive potential penetrates
through the thin target, the till then slow motion of the ponderomotive potential now begins
to pick up its speed, as the density of the plasma seen by the laser is less than the relativistic
transparent density (in terms of the timing of the interaction corresponding to time t1). Once
the laser increases its group velocity in this less dense region, only electrons can keep up with
photons, while ions are left behind. When this develops, we see that the nicely closed phase
space circle is now skewed, eventually leading to a collapse of the bucket. (See details in
Ref.Tajima (2009), there Figs. 18 and Fig. 19).
In order to further improve these situations, we envision to counteract the convex bulging by
instituting a concave shape to the target. This little manipulation may improve the energy
enhancement by a factor of a few Tajima (2005). A recent simulation demonstrates this Wang
(2010). It should also help if we adopt a cone Kodama (2002) in front of the foil, which can
collect the laser power to intensify the radiance of the laser. Wang et al. Wang (2011) have
suggested a gas medium (in front of the thin foil) that leads to the enhanced laser intensity.
To further arrest the collapsing trapping bucket by the accelerating photons after they transmit
through the thin target, we could let them slow down again by adding supplementary target
material such as dense gas/clusters, a foam target or a mesh of carbon nanotubes behind the
rear surface. Such would decrease the group velocity of the laser after it passes through the
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thin solid foil and increase the interaction time between the laser pulse and the plasma and
therefore the accelerating time for ions. With special target manufacturing techniques (e.g.
concave as looked from the rear surface) or hemispheric targets, it may be possible to increase
the power of a0 in ion energy that is important as an outlook, because at present we need a
much bigger laser if we want to reach the medical energy of 200 MeV/u. If these additional
measures can enhance the ion acceleration time, it will be perhaps possible to reduce the
necessary laser intensity and still reach the same energies, contributing to a less demanding
laser power for the necessary energy regime.
Even if the necessary energies are reached, there are many additional requirements a therapy
system needs to satisfy, as was discussed in Sec. 1. These are by no means easy tasks and
pose challenges for us researchers. On the other hand, we do have a host of new ways to
manipulate intense ion and laser beams by harnessing the relativistic dynamics of the laser
and its plasma interaction Mourou (2006). For example, our ability to simultaneously generate
an ion beam with coherent X-rays Tsakiris (2006) from the laser-thin target interaction can
allow us to perform unprecedented accurate X-ray diagnosis such as phase contrast imaging
Pfeiffer (2006). This would give us the additional ability of accurate imaging simultaneous
with therapy. With the increasing ability to detect smaller tumors, the laser driven ion therapy
method with the imaging guidance and with on-line dose verification techniques Bolton
(2010); Kormoll (2011) may become a suitable clinical option for safe treatment of small tumors
Murakami (2008).
3. Medical radioisotopes with high specific activity produced in photonuclear
reactions
The laser-driven γ beams are spurring the possible clinical usage of a novel class of
radioisotopes that are very useful for nuclear medicine but are not easy to obtain otherwise.
These radioisotopes may be delivered to specific cells/DNA/proteins/peptides of the tumor
with a specific vector drug, where cancer cells may be killed by their radioactivity. This
method is not hampered by the beam scattering of ion therapy in Sec. 2, nor restricted by
non-metastasis, which are the general limitations of EBRT.
Fig. 6. Progress in flux of γ beams (left) and (right) progress in bandwidth ∆Eγ/Eγ of
high-energy γ beams (≈ 10 MeV) for different (existing and planned) γ beam facilities.
In a new development the intense, high repetition rate, diode pumped lasers in combination
with intense, brilliant, relativistic electron beams allow to produce very intense, brilliant γ
beams via Compton back-scattering. Thus in about 2 years from now the MEGa-ray project
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at LLNL Barty (2010) will have γ beams, which have 10(4−6) times higher flux than the
best existing γ beams and it can be anticipated from ongoing developments that in 5-10
years even 104 times more intense γ beams will become available, which will allow to
produce many new medical radioisotopes for diagnostics and therapy. This is illustrated
in Fig. 6. The new γ beams will also have a much smaller band width ∆Eγ/Eγ, allowing
to address individual nuclear levels with strong population. Here, on the one hand, by
(γ,γ′) photoexcitation new nuclear isomers can be produced, which decay frequently by
many conversion and Auger electrons, allowing for a short-range killing of tumor cells in the
surrounding 10-200 µm range after they have been transported to the overexpressed acceptors
of the cancer cells. But also by (γ, xn + yp) photonuclear reactions many new medical
radioisotopes can be produced. We will discuss in detail many new specific radioisotopes. As
an example we here want to mention so-called "matched" pairs for diagnostics and therapy
of the same chemical element. Here pairs like: 44Sc/47Sc, 61Cu or 64Cu/67Cu, 86Y/90Y, 123I
or 124I/131I or 152Tb/149Tb or 161Tb are of special interest, where one of the isotopes was
so far difficult to produce by classical methods. Here the basic idea is to use bioconjugates
Schiepers (2006), that show a high affinity and selectivity to bind to peptide receptors or
antigens, that are overexpressed on certain cancer cells compared to normal cells. As shown
in Fig. 7 the suitable radioisotope is placed into the chelator end of the bioconjugate. These
therapies are called Peptide Receptor Radio Therapy (PRRT), when peptides are used as
bioconjugates or radioimmunotherapy (RIT), when antibodies are used. This therapy allows
to fight diseases, which are not localized or cancer types with multiple metastasis. Once
the suitable radioisotopes have been produced the main task stays with radiochemistry and
radiopharmaceutics to build the proper bioconjugates to reach the cancer cells in the optimum
way. While we are pushing for the treatment of very small tumors in laser-driven ion therapy,
with the new therapeutic medical radioisiotopes one is going for shorter range emitted
radiation (α particles, low-energy electrons) only killing cancer cells and cancer stem cells
in the immediate surrounding, where the bioconjugate was delivered.
Fig. 7. Schematic picture explaining how a specific radionuclide can be transported to a
specific peptide receptor.
3.1 Brilliant γ beams
In the next years γ beams, presently under construction, will become available with that much
increased flux, that a good production of medical radioisotopes becomes possible. These γ
beams are produced via Compton back-scattering of laser photons from a relativistic electron
beam. photonuclear physics is the High-Intensity γ-ray Source (HIγS) at Duke University
(USA). It uses the Compton back-scattering of photons, provided by a high-intensity
Free-Electron Laser (FEL), in order to produce a brilliant γ beam. The γ intensity in the
energy range between 1 MeV and 160 MeV amounts to 108s−1 with a band width of about
5% Weller (2009). There are plans to upgrade the facility by using infrared laser light in a
longitudinal enhancement cavity to increase the intensity to 2 ∗ 1012s−1 and the band width
to about 0.1 - 0.2 % Wu (2011). Besides the storage ring approach an approach with a electron
linac is persued. Here the project T-REX with a normal conduction S-band electron linac was
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recently terminated Albert (2010; 2011). Here a new brilliant Mono-Energetic Gamma-ray
(MEGa-ray) facility at Lawrence Livermore National Laboratory (USA) is based on a normal
conducting 12 GHz electron linac and should yield already in the beginning of 2013 for
γ energies between 0.5 and 4 MeV a γ intensity of 1013s−1 with an energy band width
of down to 10−3 and a brilliance of 1022/[mm2mrad2s 0.1%BW] Barty (2010). Using the
same accelerator technology, at the upcoming Extreme Light Infrastructure - Nuclear Physics
(ELI-NP) facility in Bucharest, a γ beam will become available until 2015, providing about
the same γ intensity and band width in the energy range of 1-25 MeV ELINP (2010). Even
more efficient interactions between electron bunches and laser pulses from diode pumped
lasers are under investigation, which will improve the γ flux from the presently given value
of 106/(eVs) by two orders of magnitude.
At present, great efforts are also invested all over the world to realize highly brilliant γ beams
based on the Energy Recovery Linac (ERL) technology. The Energy Recovery Linac (ERL)
requires a new type of superconducting electron accelerator that provides a highly brilliant,
high-intensity electron beam. The main components of an ERL are an electron injector, a
superconducting linac, and an energy recovery loop. After injection from a highly brilliant
electron source, the electrons are accelerated by the time-varying radio-frequency field of the
superconducting linac. The electron bunches are transported once through a recirculation
loop and are re-injected into the linac during the decelerating RF phase of the superconducting
cavities. So the beam dump has to take the electron bunches only with low energy, while the
main part of the electron energy is recycled. At ERLs highly brilliant γ beams can be created
by Compton back-scattering of photons with high energy (0.1-100 MeV), again recirculating
the photons in a high finesse cavity with MW power or using ring-down cavities to overcome
the small Compton cross section. ERL technology is pioneered at Cornell University (together
with Thomas Jefferson National Laboratory) Bilderback (2010a;b); Liepe (2010), where an ERL
is presently under construction for a 5 GeV, 100 mA electron beam. > 1016s−1 in an energy
range of 0.5 - 25 MeV. Such a facility would provide a brilliant pulsed γ beam with a narrow
band width much smaller than 10−3 and very high flux of (1010 − 1011)/(eVs). Since due to
thermal Doppler-boadening the nuclear levels have typical widths of a few eV, good yields
for medical isotopes are expected. For the new γ beams with better band width and small
opening angle, we may use arrays of refractory γ lenses Schroer (2005); Vaughau (2011). In
this way we could focus the γ beams to very small spot size (10 nm) for the first time and it
becomes feasible to always use enriched targets for medical radioisotopes with high specific
activity.
3.2 Presently used nuclear reactions to produce medical radioisotopes
Today the most frequently employed nuclear reactions for the production of medical
radioisotopes are:
1. Neutron capture Neutron capture (n,γ) reactions transmute a stable isotope into a
radioactive isotope of the same element. High specific activities are obtained, if the (n,γ)
cross section is high and the target is irradiated with a high neutron flux. Neutrons
most useful for (n,γ) reactions have energies from meV to keV (thermal and epithermal
neutrons) and are provided in the irradiation positions of high flux reactors at flux densities
of 1014 n/(cm2s) up to few 1015 n/(cm2s). If the neutron capture cross section is sufficiently
high (e.g. 2100 barn for 176Lu(n,γ)177Lu), then a good fraction of the target atoms can be
transmuted to the desired product isotopes, resulting in a product of high specific activity.
2. Nuclear fission Fission is another process used for isotope production in nuclear reactors.
Radiochemical separation leads to radioisotopes of “non-carrier-added” quality, with
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specific activity close to the theoretical maximum. Fission is the dominant production
route for the generator isotopes 99Mo and 90Sr, for the β− emitting therapy isotope 131I
and for the SPECT isotope 133Xe.
3. Charged particle reactions with p, d or α ions Imaging for diagnostic purposes requires
either β+ emitters for PET (mainly 18F, 11C, 13N, 15O, 124I, or 64Cu), or isotopes emitting
gamma-rays with suitable energy for SPECT (about 70 to 300 keV), if possible without
β+/− emission to minimize the dose to the patient. Thus electron capture decay is
preferred for such applications, e.g.: 67Ga, 111In, 123I, 201Tl. Usually these neutron-deficient
isotopes cannot be produced by neutron capture on a stable isotope (exception 64Cu).
Instead, they are mainly produced by charged-particle induced reactions such as (p,n),
(p,2n),. . . High specific activities of the final product are achievable, if the product differs in
chemical properties from the target (i.e. different Z) and can be chemically separated from
the remaining bulk of target material. Thus Z must be changed in the nuclear reaction,
e.g. in (p,n), (p,2n), (p,α) reactions. The energies of the charged particle beams for such
reactions are usually in the range of 10 to 30 MeV and can be supplied with high currents
(0.1 to 1 mA) by small cyclotrons.
4. Generators Another important technique is the use of generators, where short-lived
radionuclides are extracted “on-tap” from longer-lived mother nuclides. Here the primary
radioisotope (that was produced in the nuclear reaction) has a longer half-life than the
final radioisotope (that is populated by decay of the primary radioisotope and is used in
the medical application). The primary radioisotope is loaded onto the generator and stays
there chemically fixed. The final radioisotope will grow in and can be repetitively eluted
and used.
5. Photonuclear reactions The inverse process to (n,γ), namely (γ,n), also allows producing
neutron deficient isotopes, but conventional γ ray sources do not provide sufficient flux
density for efficient production of radioisotopes with high total activity and high specific
activity. Therefore, this process played no role until now.
4. Specific radioisotopes produced in photonuclear reactions
We now discuss in detail the different γ-induced reactions and specific radioisotopes
that can be produced by photonuclear reactions, that are enabled by the aforementioned
breakthroughs of brilliant γ beam technology. In Tables 1 and 2 we show estimates of the
achievable specific activities for thin targets for a γ flux of 1014 per s, corresponding to a flux
density of 1018 γ/(cm2 s) for a beam cross-section of (0.1mm)2. With a bandwidth of 10−3, this
results at 10 MeV in a spectral flux density of 1014 γ/(cm2 s eV). With γ lenses the beam cross
section could be improved by 104 and a better bandwidth is expected. We compare these to
thin-target yields obtained by thermal neutron capture at a typical flux density of 1014 n/(cm2
s) in high flux reactors. Note that alike for the potential beam parameters of γ beam facilities,
there is also a wide range of flux densities available at the irradiation positions of high flux
reactors. Some positions provide flux densities of several 1012 to 1013 n/(cm2 s), while few
special reactors have positions that even exceed 1015 n/(cm2 s), namely SM3 in Dimitrovgrad
Karelin (1997), HFIR in Oak Ridge Knapp (2005) and the ILL’s high-flux reactor in Grenoble.
Since hitherto no γ beams with sufficiently small bandwidth were available to exploit
resonant excitation, there are obviously no such measured cross-sections. Presently, we can
only estimate a lower bound using the averaged cross-sections measured at bremsstrahlung
facilities Carroll (1991;a;b); data (2010); Neumann (1991). For cases where no measured
cross-sections are available, we interpolate experimental cross-sections of the same reaction
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channel on nearby elements, taking into account the energy above the reaction threshold.
We have submitted a proposal to the HIγS facility to measure the expected strong resonant
gateway states for radioisotope production, which frequently can be predicted from known
neighboring nuclei.
Even when using conservative assumptions, the estimated specific activities are promising for
specific isotopes.
The total radioisotope activity achievable in a nuclear reactor can be relatively high since, thick
(several cm) and large (several cm2) targets can be used if the cross-sections are not too high
(leading to self absorption and local flux depression). Multiple irradiation positions allow
producing various radioisotopes with activities of many TBq.
For the γ beam we estimate the total activities by integrating to one interaction length, i.e.,
where the initial γ-beam intensity has dropped to 1/e = 37 % of its intensity. Higher total
activities can be achieved with thicker targets at the expense of lower specific activity and
vice versa. The total interaction cross-section is usually dominated by the atomic processes
of Compton effect and pair creation, but not for γ beams with very small bandwidth. We
conservatively consider any γ ray as lost after interaction. In reality, part of the Compton
scattering goes forward under small angles and the γ rays that have lost little energy can still
induce photonuclear reactions. The usable target thickness ranges from 20 g/cm2 for heavy
elements to 40 g/cm2 for light elements, i.e., in total only few mg target material are exposed
to the small area of the γ beam. With non-resonant reactions of the order of 0.1 TBq activity
can be produced per day, corresponding to tens (for β− therapy isotopes) to thousands (for
imaging isotopes and therapy with alpha emitters) of patient doses.
4.0.1 Isomers of stable isotopes via (γ, γ′) reactions
For various applications in nuclear medicine longer-lived nuclear isomers that decay by
emission of gamma rays and/or conversion electrons to the respective ground state are of
Iso- Isomer Iis/Igs Ground state σ · Γ Sep. Act. Rγ Sp.Ac. Rγ/
tope Exc. Spin & T1/2 Spin & Nat. at 4 at 6 Act. 1/d fraction high flux R(n,γ)
energy parity parity abun. MeV MeV of max. reactor
keV d % eV·b eV·b γ GBq GBq/mg
87Sr 389 1/2− 0.12 3.5 9/2+ 7 3.9 8.7 10 110 2·10−5 0.57 18
115In 336 1/2− 0.19 9/2+ 95.7 18 67 58 603 3·10−4
117Sn 315 11/2− 13.8 0.04 1/2+ 7.68 3.2 8.8 7.5 0.6 0.0025 0.003 2400
123Te 248 11/2− 119 0.13 1/2+ 0.89 42 68 55 0.6 0.17 0.2 280
125Te 145 11/2− 57.4 0.17 1/2+ 7.07 70 0.08 0.48
129Xe 236 11/2− 8.9 0.10 1/2+ 26.4 0.2
131Xe 164 11/2− 11.8 0.10 3/2+ 21.2 0.2
135Ba 268 11/2− 1.2 0.08 3/2+ 6.59 13 60 44 33 1.5·10−3 0.045 1000
176Lu 123 1− 0.15 2.0 7− 2.59 140 350 2.0 1800 1.2·10−3 5.5 36
195Pt 259 13/2+ 4.02 0.09 1/2− 33.8 30 140 72 17 0.012 0.019 3800
Table 1. Longer-lived nuclear isomers produced in (γ,γ′) reactions. The relative population
of the respective isomer in thermal neutron capture on A-1 target isotopes is given as Iis/Igs
where known experimentally. Experimental integrated cross sections for population of the
isomer by (γ,γ′) reactions at 4 MeV and 6 MeV were taken from Carroll (1991;a). The
fraction of the maximum specific activity Rγ produced in (γ,γ′) reactions is put in relation to
the one obtained with (n,γ) reactions R(n,γ) at a thermal neutron flux of 10
14 n/(cm2 s) in the
last column.
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interest, if they can be produced with high specific activity. Table 1 shows a selection of such
isomers.
Most usual production methods, e.g., via (n,γ) reactions, result in relatively low specific
activity, since the dominant part of the production proceeds directly to the nuclear ground
state that has a nuclear spin closer to that of the A-1 target isotope. However, the fact that
all these isomers are actually populated via thermal neutron capture reactions on low-spin
A-1 target isotopes proofs that pathways populating the high-spin isomers from higher-lying,
low-spin compound nucleus resonance levels of lower spins must exist. In Ref. Lendoux
(2006) the population of high-spin isomers relative to the ground state was studied for
resonances in (n,γ) reactions. An energy dependence of the isomeric ratio was observed. One
may expect that this energy dependence would become even more pronounced if the reactions
were excited with a primary beam of smaller bandwidth that populates more selectively states
which decay mainly to the isomeric level of interest.
Also photoexcitation (γ,γ′) experiments with bremsstrahlung beams were performed on a
series of stable targets and showed strong population of isomeric levels Carroll (1991;b);
Neumann (1991). The observed energy dependence of the isomer activation yields indicates
that few gateway states are responsible for efficiently populating the isomers.
Moreover, photoexcitation with small-bandwidth γ rays allows the selective excitation of
individual levels or groups of levels that decay preferentially to the nuclear isomer, thus
enhancing the specific activity of the isomer. Only in few cases the energies of such (groups
of) levels are already known. Note that relatively low gamma ray energies may be sufficient
for such a pumping to isomeric states. In 125Te a 7/2+ state at only 402 keV excitation energy
can serve as gateway state for pumping from the 1/2+ ground state to the 11/2− isomer at
145 keV NuDAT (n.d.).
We will estimate the achievable specific activity at the example of 115In, for which the required
transition energies, branching ratios and transition strengths are already experimentally
known, even if this isomer has presently no application in nuclear medicine.
Experimental data on isomer population by (γ,γ′) reactions have so far been obtained with
bremsstrahlung spectra of large bandwidth. The integrated cross-sections at γ energies of 4
and 6 MeV, respectively, are of the order of 10 to 100 b·eV.
Many potential gateway states that could serve for pumping nuclei from their ground state
to isomeric levels are expected to exist, but they still need to be identified by dedicated
high resolution measurements from excitation energies of few hundred keV up to close to
the particle separation energy. These measurements have to be performed with the new
γ beams for each of the isotopes for variable energy windows, in order to determine the
best excitation-deexcitation path to the isomer. Presently existing γ-ray beam facilities only
marginally provide sufficiently monochromatic γ-ray beams to search for suitable resonance
regions. A systematic investigation will require Compton backscattering facilities such as
MEGa-ray (LLNL) or ELI-NP.
Selecting γ ray energies providing strong pumping to the isomeric state will improve the
achievable specific activity correspondingly. Even multiple excitations of the path to the
isomer are possible. Due to the missing energy match, no significant back-pumping from
the isomer to the ground state will occur.
maximum specific natural abundance and assume that finally will result in a total conversion
of the ground than presently
Two examples of long-lived isomers with important medical applications are discussed in the
following:
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1. 195mPt: Platinum compounds such as cisplatin or carboplatin are known to be cytotoxic
and are frequently used for chemotherapy of tumors. Labeling these compounds with
platinum radiotracers allows for in-vivo pharmacokinetic studies and tumor imaging, e.g.,
to monitor the patient-specific uptake and optimize the dosing individually Dowell (2000).
Failure to demonstrate the tumor uptake of the chemotherapy agent by nuclear imaging
helps to exclude those “non-responding” patients from unnecessary chemotherapy
treatment. 195mPt has 4 days half-life and emits a 99 keV gamma ray that can be used
for imaging by SPECT or gamma cameras. 195mPt emits also low-energy conversion and
Auger electrons. Hence, when used in higher activities, it could be suitable for a combined
chemo- and radionuclide therapy. Unfortunately, 195mPt is destroyed by (n,γ) reactions
with a very high cross section of 13000 barn. Therefore the specific activity achievable by
neutron capture on 194Pt is seriously limited.
2. 117mSn: Also, 117mSn emits low-energy conversion and Auger electrons, making it
promising for radionuclide therapy. In addition it emits a 159 keV gamma ray for imaging.
It has been shown that 117mSn can be used for pain palliation in bone metastases of various
cancers. Due to its soft electron energy spectrum, it has less side effects on the bone marrow
than other radioisotopes with more penetrating radiation Bishayee (2000).
These two isomers appear at present most interesting for nuclear medicine applications.
The specific activity and total production per day could be significantly improved with still to
be found better gateway states. A detailed search for suitable gateway states at an upcoming
γ-beam facility with small bandwidth is underway.
4.1 Radioisotopes via the (γ,n) reaction
When excited well beyond the neutron binding energy, a nucleus readily loses a neutron.
Competing reactions such as deexcitation by gamma ray emission are far less probable.
1. 99Mo/99mTc: The presently most used radioisotope for nuclear medicine studies is 99mTc.
Its 140 keV γ ray is ideal for SPECT imaging. With a relatively short half-life of 6 h and the
quasi-absence of beta particles, the radiation dose to the patient is sifficiently low. 99mTc
is conveniently eluted in non-carrier-added quality from simple and reliable 99Mo (T1/2 =
66 h) generators that can be used for about one week. Various technetium compounds have
been developed for a multitude of nuclear medicine applications Schiepers (2006). The
combination of these advantages explains why 99mTc is used in about 80% of all nuclear
medicine studies. Until recently five nuclear reactors were used to produce about 95 %
of the world needs of 99Mo by neutron-induced fission of highly enriched 235U targets.
Recently the two reactors that used to produce the majority of the 99Mo supply had
extended shutdowns, leading to a serious 99Mo/99mTc supply crisis Lewis (2009); Raloff
(2009). A facility providing 1015γ/s could produce via 100Mo(γ,n) reactions several TBq
per week. Since the present request is 3000TBq per week, many such facilities would be
required to assure the worldwide 99Mo supply.
This example demonstrates that the new production method by γ beams is not intended to
compete with large-scale production of established isotopes. The advantage of γ beams for
radioisotope production lies clearly in the very high specific activity that can be achieved
for radioisotopes or isomers that are very promising for nuclear medicine, but that are
presently not available in the required quality or quantity.
2. 225Ra/225Ac: Alpha emitters are very promising for therapeutic applications, since the
emitted alphas deposit their energy very locally (typical range of one to few cancer
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Product T1/2 Target Rct. Eγ σ Spec. act. Activity Rγ Spec. act. Rγ/R(n,γ)
isotope isotope γ beam per day fraction HFR
d MeV b GBq/mg GBq of max. GBq/mg
47Ca 4.5 48Ca (γ,n) 19 0.09 1100 400 0.05 0.9 1200
64Cu 0.5 65Cu (γ,n) 17 0.09 830 1150 0.006 4 200
99Mo 2.8 100Mo (γ,n) 14 0.16 960 350 0.06 0.08∗ 12000
103Pd 17 104Pd (γ,n) 17 0.05 290 16 0.1 1.8 160
165Er 0.4 166Er (γ,n) 13 0.3 1100 1100 0.016 4.7 230
169Er 6.9 170Er (γ,n) 12 0.3 ≈ 800 130 ≈ 0.2 0.8 1000
13 0.3 ≈ 200 30 ≈ 0.5 170
186Re 3.7 187Re (γ,n) 15 0.6 ≈ 1400 320 ≈ 0.2 35 40
225Ra 14.8 226Ra (γ,n) 12 0.2 ≈ 300 30 ≈ 0.2
47Sc 3.4 48Ti (γ,p) 19 0.02 250 100 0.009
67Cu 2.6 68Zn (γ,p) 19 0.03 260 115 0.01
44Ti 60 y 46Ti (γ,2n) 27 0.01 ≈ 0.5 0.008 ≈ 0.1
22 0.02 ≈ 25 0.7 ≈ 0.1
84Sr (γ,2n) 25 0.02 140 5.6 0.06
224Ra 3.7 226Ra (γ,2n) 16 0.1 ≈ 50 10 ≈ 0.01
Table 2. Estimated production rates of radioisotopes produced in (γ,n), (γ,p) or (γ,2n)
reactions. Experimental cross sections were taken from data (2010), estimated cross sections
are marked in italics. The fraction of the maximum specific activity produced in (γ,x)
reactions Rγ, is put in relation to that obtained with (n,γ) reactions R(n,γ) at a thermal
neutron flux of 1014 n/(cm2 s) in the last column. ∗: For comparison we show the values for
99Mo produced by 98Mo(n,γ). However, usually 99Mo is produced by fission with much
better specific activity.
cell diameters) with high linear energy transfer (LET) and, hence, high probability
for irreparable double strand breaks. An alpha emitter coupled to a cancer cell
specific bioconjugate can be used for targeted alpha therapy to treat disseminated
cancer types (leukemia), micro-metastases of various cancers or to destroy chemo- and
radiation-resistant cancer cells (e.g., glioblastoma). One promising alpha emitter is 225Ac
(T1/2 = 10 days) that decays by a series of four alpha decays and two beta decays to
209Bi.
3. 169Er: 169Er decays with 9.4 days half-life by low-energy beta emission (100 keV average
beta energy). These betas have a range of 100 to 200 µm in biological tissue, corresponding
to few cell diameters. The short beta range makes this isotope very interesting for targeted
radiotherapy Uusijaervi (2006).
4. 165Er: 165Er is one example for an isotope that decays mainly by low-energy Auger
electrons. Their range is shorter than one cell diameter. Hence, these Auger emitters have
to enter the cell and approach the cell’s nucleus to damage the DNA and destroy a cell.
Coupled to a bioconjugate that is selectively internalized into cancer cells it can enhance
the ratio for dose equivalent delivered to the tumor cell with respect to normal cells. This
should result in an improved tumor treatment with less side effects.
5. 47Sc: 47Sc is a promising low-energy beta emitter for targeted radiotherapy. Scandium
is the lightest rare earth element. Most established labeling procedures for valence III
metals (Y, Lu,. . . ) can be applied directly for Sc. Its 159 keV gamma line allows imaging of
47Sc distribution by SPECT or gamma cameras. Alternatively, the β+ emitting scandium
isotope 44Sc can be used for PET imaging as a “matched pair”. Carrier-free 47Sc can be
produced by 50Ti(p,α) or 47Ti(nfast,p) reactions followed by chemical separation. The
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alternative production via 46Ca(n,γ)47Ca→47Sc is uneconomic due to the extremely low
natural abundance of 46Ca.
6. 64Cu: 64Cu is a relatively long-lived β+ emitter (T1/2 = 12.7 h) with various applications
in nuclear medicine Anderson (2009). 64Cu-ATSM is a way to measure hypoxia of tumors.
Hypoxia is an important effect influencing the resistance of tumor cells against chemo- or
radiation therapy. 64Cu can also act itself as therapeutic isotope due to its emission of β−
(191 keV mean energy) and low-energy Auger electrons.
7. 186Re: 186Re is a radioisotope suitable for bone pain palliation, radiosynovectomy and
targeted radionuclide therapy. Rhenium is chemically very similar to its homologue
technetium, thus known compounds that have been developed for imaging with 99mTc
can also be labeled with 186Re and used for therapy. 186Re is currently either produced
by neutron capture on 185Re, resulting in limited specific activity, or by 186W(p,n) reactions
followed by chemical Re/W separation. Enriched 187Re targets should be used to minimize
contamination of the product with long-lived 184,184mRe by 185Re(γ,n) reactions.
4.2 Radioisotopes via the (γ,p) reaction
Even when excited beyond the proton binding energy, a nucleus does not necessarily lose
a proton. The latter is bound by the Coulomb barrier, leading to a suppression of the
proton loss channel. Only for an excitation well beyond the proton binding energy, the
proton gains enough kinetic energy for tunneling efficiently through the Coulomb barrier.
However, such excitation energies are usually also above the neutron binding energy or even
the two-neutron binding energy. Hence neutron emission competes with proton emission and
the cross sections for (γ,p) reactions may be one order of magnitude lower than the competing
channels. Thus, the achievable specific activity (specific activity with respect to the target
mass) is limited for (γ,p) reactions. However, the product isotope differs chemically from
the target since it has one proton less (Zproduct = Ztarget − 1). After irradiation, a chemical
separation of the product isotope from the target can be performed, ultimately resulting in
a high specific activity that is only compromised by competing reactions leading to other
isotopes of the product element (such as (γ,np), (γ,2n)EC/β+, etc.) or product burn-up by
(γ,n).
1. 47Sc: Besides the 48Ca(γ,n)47Ca→47Sc reaction, 47Sc can also be produced via the 48Ti(γ,p)
47Sc reaction. The established Sc/Ti separation schemes can be employed for the chemical
processing. Compared to the 47Ti(n,p) way here the direct production of disturbing
long-lived 46Sc (via 46Ti(n,p) or 47Ti(γ,p), respectively) can be limited more easily, since
48Ti is the most abundant titanium isotope and can be enriched more easily to high
abundance. However, the irradiation times have to be kept relatively short to prevent
excessive formation of 46Sc impurity by 47Sc(γ,n) reactions.
2. 67Cu: 67Cu is also a promising beta-emitter for targeted radiotherapy. Alike 47Sc it has a
sufficiently long half-life for accumulation in the tumor cells when bound to antibodies
and its 185 keV gamma ray allows imaging with SPECT or gamma cameras. Together with
the PET imaging isotopes 61Cu or 64Cu, it forms a “matched pair”. The usual production
routes 68Zn(p,2p), 70Zn(p,α), or 64Ni(α,p) are all characterized by low yields. The former
requires energetic protons (≫ 30 MeV from larger cyclotrons) and the latter two methods
use expensive enriched targets with low natural abundances.
3. Isotopes with higher Z: In principle, also heavier β− emitters used for radionuclide
therapy such as 131I, 161Tb or 177Lu could be produced by (γ,p) reactions (on 132Xe, 162Dy
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or 178Hf targets respectively). However, for higher Z the increasing Coulomb barrier leads
to small production cross sections.
thyroid problems. produced by thermal neutron-induced fission of enriched 235U targets.
be produced via 132Xe(γ,p) reactions. particularly useful thin xenon gas targets. The
handling of highly active stream is stongly reduced. Strongly enriched 132Xe can be
obtained ?. gas target is straightforward, e.g. xenon gas cell with sterile water established
t 124Xe(p,2n) the thermal stress of the due to the Moreover the full recovery essentiel far
cheaper than 124Xe.
short-lived 225Fr that 225Ra. This reaction can be used simultaneously to production.
4.2.1 Radioisotopes via the (γ,2n) reaction
1. 44Sc: 44Sc is a promising metallic PET tracer that emits a 1157 keV gamma-ray
quasi-simultaneously with the positron. With a suitable detection system (Compton
telescope plus PET camera), a triple coincidence (gamma rays of 511 keV, 511 keV, and
1157 keV) can be detected Grignon (2007). Hence, for each triple-event the point of
emission is derived instead of the usual line-of-response, leading to improved position
resolution at reduced dose to the patient. Moreover, 44Sc forms a “matched pair” with 47Sc,
a therapy isotope discussed above. 44Sc can be obtained from 44Ti/44Sc generators where
the parent isotope 44Ti is very long-lived (T1/2 = 60 years). Despite the very favorable
properties of 44Sc, this isotope is not yet used in clinical routine, since the generator isotope
44Ti is difficult to produce and therefore prohibitively expensive until now.
conveniently eluted on-site from generators and used for various ?. The great interest in
68Ga rapidly rising demand for presently produced by 69Ga(p,2n) reactions that alternative
production path.
β+ emitter is continuously 82Sr/82Rb of heart and brain. imaging with 99mTc ?.
PET imaging and the present 99Mo/99mTc supply 82Sr/82Rb generators. produced in
85Rb(p,4n)82Sr reactions. few large cyclotrons or linear accelerators exist world-wide that
(≥ 60 MeV) for efficient 85Rb(p,4n)82Sr reaction. by photonuclear 84Sr(γ,2n)82Sr high
specific activities are reached not to compromise sufficiently high per day
2. 224Ra/212Pb/212Bi: Via 226Ra(γ,2n) reactions the isotope 224Ra (T1/2 = 3.66 d) from the
thorium chain can be obtained, where the noble gas 220Rn isotope can be extracted easily.
The α emitter 212Bi (T1/2 = 60 min) in this decay chain or its mother isotope
212Pb are also
considered for targeted alpha therapy, e.g., for malignant melanoma metastases Hassfjell
(2001); Mia (2005).
With the new γ beam facilities like ELI-NP or MEGa-ray LLNL we will search for optimum
gateway states for all these new medical radioisotopes, making the production cross section
much more reliable.
5. Conclusion
The advance of intense laser technology Mourou (2006) is changing the reach of laser-driven
approaches of radiotherapy, both in the EBRT and in the endoradiation therapy, taking
advantage of the new brilliant γ beams. In terms of EBRT, the laser-driven ion beam therapy
awaits the rapid progress in the understanding of laser ion acceleration, both theoretically
and experimentally. Theoretically, the recent year’s research now directs us where the "sweat
spots" in reaching 100-200 MeV ion/nucleon with a 100-200 TW laser. Experimentally, so
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far often with less than 100 TW lasers we now see convergence of experimental results with
theory of more efficient regimes such as CAIL/RPA. Thus when near future experiments are
expected to embark on PW lasers, these experiments should reveal not only sufficiently high
ion energies mentioned above, but also the parameters and configurational dependencies for
the "sweat spots". We then can optimize the overall best spots of operation. In going to
smaller tumors (≤ cm regime), it is important to develop the image guided irradiation with
pencil beams (e.g. Ref. Sutherland (2010)), the online dosimetry with sufficiently agile novel
methods of detection such as prompt γ detection from the proton beam collisions with tissue
nuclei Kormoll (2011). Such guidance, irradiation, and dose confirmation can make up an
active feedback dose delivery by a radio-oconcologist Murakami (2008) first time ever. This
approach should lead to more accurate dose control over small tumors. This concept matches
with the desire of the radiooncologist Molls (2009) to treat early small tumors, but also opens
the avenue through which the laser-driven particle therapy can find niches when this method
is ill-suited for larger tumors. The fledgling irradiation demonstrations by laser-driven proton
beams on in vivo cells have shown, so far, the radiological effectiveness not far different from
conventional accelerators Kraft (2010); Yogo (2009).
For the production of medical radioisotopes for nuclear medicine, we develop generalized
nuclear models of doorway states for optimum production and start testing them with
present γ beams of improved band width, compared to formerly published broad band
width measurements. Even in the old measurements very strong variations of the production
cross sections between different isotopes had been observed Carroll (1991), pointing to a
nonstatistical cross section behavior. Thus we expect to find with MEGa-ray (LLNL) and
ELI-NP in the next 3-5 years improved resonant cross sections, making this alternative way of
medical radioisotope production more favorable and economical. The resonantly enhanced
strong cross sections, with their narrow width compete much more favorably with the always
present atomic cross sections. With these new intense, brilliant γ beams and γ optics the area
of nuclear photonics starts, where nuclear collective doorway states are not only interesting
from the perspective of nuclear modelling, but reach applicational importance like in nuclear
medicine.
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Currently there have been many armamentaria to be used in cancer treatment. This indeed indicates that the
final treatment has not yet been found. It seems this will take a long period of time to achieve. Thus, cancer
treatment in general still seems to need new and more effective approaches. The book "Current Cancer
Treatment - Novel Beyond Conventional Approaches", consisting of 33 chapters, will help get us physicians as
well as patients enlightened with new research and developments in this area. This book is a valuable
contribution to this area mentioning various modalities in cancer treatment such as some rare classic
treatment approaches: treatment of metastatic liver disease of colorectal origin, radiation treatment of skull
and spine chordoma, changing the face of adjuvant therapy for early breast cancer; new therapeutic
approaches of old techniques: laser-driven radiation therapy, laser photo-chemotherapy, new approaches
targeting androgen receptor and many more emerging techniques.
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